MedTrace Logo

The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants

NCT05829551 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2023-04-25

No results posted yet for this study

Summary

This is double-blind,randomized, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety, tolerability and drug-drug interaction of RAY1216, and the effect of food on RAY1216 Pharmacokinetics.

Conditions

  • COVID-19 (Coronavirus Disease 2019)

Interventions

DRUG

RAY1216 dose 1

RAY1216 dose 1 or Placebo

DRUG

RAY1216 dose 2

RAY1216 dose 2 or Placebo

DRUG

RAY1216 dose 3

RAY1216 dose 3 or Placebo

DRUG

RAY1216 dose 4 &ritonavir

RAY1216 dose 4 \&ritonavir or Placebo

DRUG

RAY1216 dose 5

RAY1216 dose 5 or Placebo

DRUG

RAY1216 dose 6

RAY1216 dose 6 or Placebo

DRUG

RAY1216 dose 7

RAY1216 dose 7 or Placebo

DRUG

RAY1216 dose 8

RAY1216 dose 8 or Placebo

DRUG

RAY1216 dose 9

RAY1216 dose 9 or Placebo with high fat meal

DRUG

RAY1216 dose 10

RAY1216 dose 10 or Placebo with high fat meal

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-20
Primary Completion
2022-08-12
Completion
2022-08-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05829551 on ClinicalTrials.gov